ASX Announcements
Memphasys is committed to providing shareholders with complete, up-to-the-minute information about the Company. Contact, stock, and corporate information can be found in this section of the website and on the Australian Securities Exchange.
2026 ASX Announcements
17 April 2026 – Quarterly Report – Period Ended 31 March 2026
7 April 2026 – Memphasys Investor Webinar and Release of Updated Investor Presentation
20 March 2026 – Memphasys Maintains Uninterrupted Middle East Operations
27 February 2026 – Quarterly Report – Period Ended 31 March 2026
9 February – Memphasys Secures TGA Approval for Felix System
3 February – Regulatory Submissions Lodged as Felix™ Commercial Momentum Builds Across Australia, India and the United Kingdom
2 February – Qatar’s Largest IVF Institution Places First Major Repeat MENA Orders for Felix™
22 January – December 2025 Quarterly Activities Report and Appendix 4C
2025 ASX Announcements
30 December 2025 – Memphasys Extends Convertible Note Repayment Terms
29 December 2025 –Memphasys Secures CE Mark Approval for Felix System
23 December 2025 – Memphasys Secures Long-Term European Supply Agreement
18 December 2025 – Key MENA Partner Secures Early Felix™ Cartridge Order
10 December 2025 – Memphasys Implements Leadership Restructure
8 December 2025 – Felix Middle East Direct Sales Strategy
20 November 2025 – 2025 AGM Results
November 2025 – Laser-focused on FelixTM Commercialisation – INVESTOR PRESENTATION
20 November 2025 – Chair Address to Shareholders
11 November 2025 – Section 708A Cleansing Statement
10 November 2025 – Completion of Entitlement Offer to Support Felix™ Commercialisation Activities
31 October 2025 – September 2025 Quarterly Activities Report and Appendix 4C
28 October 2025 – Memphasys Accelerates Growth with Indian Commercial Supply Agreement Under New Global Go-Direct Strategy
24 October 2025 – Memphasys Expands Felix Commercial Footprint in Japan
20 October 2025 – Response to ASX Aware Letter
20 October 2025 – Board Changes
10 October 2025 – Rights Issue Prospectus despatched
8 October 2025 – Company Secretary Appointment/Resignation
2 October 2025 – Target Market Determination
2 October 2025 – ENTITLEMENT OFFER PROSPECTUS
1 October 2025 – Cleansing Statement
30 September 2025 – Adjustment to FY25 Results
25 September 2025 – Laser-focused on Felix Commercialisation ASX | MEM – INVESTOR – PRESENTATION
22 September 2025 – Memphasys’ Placement Accelerates FelixTM Commercialisation and Manufacturing Scale-Up, Operating Costs Slashed by 40%
18 September 2025 – Trading Halt
18 September 2025 – Memphasys Secures Significant ITL Contract Upgrade to $390K and Territory Expanded to 1st EU-member State, Turkey
8 September 2025 – Memphasys Signs Exclusive Middle East Partnership, Unlocking Growth for Felix™
8 August 2025 – A high-impact, high-potential opportunity in global growth markets
30 July 2025 – June 2025 Quarterly Activity Report and Appendix 4C
25 July 2025 – Board Update
25 July 2025 – 2025 General Meeting | Change of Meeting Venue
9 July 2025 – Notice of General Meeting
30 June 2025 – Appendix 4E- Preliminary final report
30 June 2025 – Memphasys Submits CE Mark Application for Felix™
19 June 2025 – Appointment of Non-Executive Director
26 May 2025 – Change of Auditor
8 May 2025 – RoXsta™ Mega Cell High-Throughput trial
30 April 2025 – Global Clinical Validation Positions Memphasys
14 April 2025 – Binding Commitments Secured (A$1.275m)
3 April 2025 – RoXstaTM Oxidative Stress Measurement in Cattle
24 March 2025 – Felix™ Pivotal Clinical Trial Confirms Best-in-Class
13 March 2025 – R&D Tax Rebate Loan
28 February 2025 – Extension of Convertible Notes
28 February 2025 – Half Year Report
26 February 2025 – Unlocking Global Market Potential
24 February 2025 – Felix™ Clinical Trial Data Lock Completed
17 February 2025 – Brazil IVF Market Expansion
11 February 2025 – Final Patient Visit in Felix™ Trial
16 January 2025 – RoXstaTM Diagnostic Potential Publication
6 January 2025 – FelixTM Utilisation Testing in China (Heranova)